Plus Therapeutics Inc
PSTV0.260USD
+0.026+11.12%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
34.20MMarket Cap
LossP/E TTM
More Details of Plus Therapeutics Inc Company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Plus Therapeutics Inc Info
Ticker SymbolPSTV
Company namePlus Therapeutics Inc
IPO dateAug 09, 2000
CEOHedrick (Marc H)
Number of employees21
Security typeOrdinary Share
Fiscal year-endAug 09
Address4200 Marathon Blvd.
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78756
Phone17372557194
Websitehttp://www.plustherapeutics.com/
Ticker SymbolPSTV
IPO dateAug 09, 2000
CEOHedrick (Marc H)
Company Executives of Plus Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
339.79K
+159681.00%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
139.33K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
339.79K
+159681.00%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
139.33K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2018
By BusinessUSD
Name
Revenue
Proportion
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
By RegionUSD
Name
Revenue
Proportion
Japan
2.06M
77.05%
Americas
293.00K
10.97%
EMEA
270.00K
10.11%
Asia Pacific
50.00K
1.87%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
Shareholding Stats
Updated: 2 hours ago
Updated: 2 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
6.71%
The Vanguard Group, Inc.
1.24%
S.H.N. Financial Investments Ltd
0.81%
UBS Financial Services, Inc.
0.48%
Geode Capital Management, L.L.C.
0.44%
Other
90.32%
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
6.71%
The Vanguard Group, Inc.
1.24%
S.H.N. Financial Investments Ltd
0.81%
UBS Financial Services, Inc.
0.48%
Geode Capital Management, L.L.C.
0.44%
Other
90.32%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.87%
Corporation
0.81%
Investment Advisor/Hedge Fund
0.77%
Individual Investor
0.34%
Hedge Fund
0.01%
Other
89.19%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
43
6.32M
3.43%
+3.23M
2025Q3
35
3.61M
7.19%
+1.73M
2025Q2
35
2.30M
3.80%
-2.38M
2025Q1
40
2.31M
11.85%
+1.40M
2024Q4
42
829.50K
14.07%
-98.90K
2024Q3
44
822.91K
13.96%
-122.82K
2024Q2
46
793.04K
13.90%
-131.21K
2024Q1
46
164.14K
3.77%
-119.25K
2023Q4
47
203.09K
4.50%
+1.47K
2023Q3
47
127.65K
2.90%
-110.39K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
1.45M
1.05%
+1.41M
+4346.17%
Sep 30, 2025
S.H.N. Financial Investments Ltd
1.50M
1.09%
+614.55K
+69.40%
Aug 14, 2025
UBS Financial Services, Inc.
623.87K
0.45%
+536.24K
+611.88%
Sep 30, 2025
Geode Capital Management, L.L.C.
813.25K
0.59%
+762.07K
+1489.12%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
469.39K
0.34%
+462.43K
+6644.09%
Sep 30, 2025
State Street Investment Management (US)
341.89K
0.25%
+341.89K
--
Sep 30, 2025
Hedrick (Marc H)
180.11K
0.13%
+159.68K
+781.79%
Oct 01, 2025
Northern Trust Investments, Inc.
265.49K
0.19%
+265.49K
--
Sep 30, 2025
Scientech Research LLC
146.65K
0.11%
+146.65K
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
